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Abstract: Parasitic diseases are a huge burden on human health causing 
significant morbidity and mortality. However, parasitic structure based drug 
discovery programmes have been hindered by a lack of high resolution structural 
information from parasitic derived proteins and have largely relied upon 
homology models from mammalian systems. The recent renaissance in electron 
microscopy (EM) has caused a dramatic rise in the number of structures being 
determined at high resolution and subsequently enabled it to be thought of as a 
tool in drug discovery. In this review, we discuss the challenges associated with 
the structural determination of parasitic proteins. We then discuss the reasons 
behind the resurgence in EM, how it may overcome some of these challenges 
and provide examples of EM derived parasitic protein structures. Finally, we 
discuss the challenges which EM needs to overcome before it is used as a 
mainstream technique in parasitic drug discovery. 
Keywords: Electron Microscopy, Structure based drug design, Plasmodium 
falciparum, Parasitic disease. 
1. Introduction 
 
Parasitic protozoa are responsible for causing a wide range of devastating diseases, 
predominantly in the developing world1,2. Diseases such as malaria, leishmaniasis, 
toxoplasmosis and sleeping sickness are a significant global burden with over ~500 
million people affected each year, and in 2015, it was estimated that 429,000 people 
died from malaria alone3. Current therapies are limited, exacerbated by drug 
resistance for many anti-malarial compounds and no effective treatments for the 
bradyzoite form of Toxoplasma4. Therefore, there is an urgent need for new 
medicines. There have been many different approaches to designing new therapeutics 
for parasitic targets including high throughput screens (HTS), phenotypic screens and 
structure based drug design (SBDD)5. Drug discovery campaigns can be significantly 
enhanced when the 3D structural information of the protein target is known, especially 
if the protein is bound to an inhibitor allowing the mode of binding to be established6. 
This information can be utilised by medicinal chemists in the design of new compounds 
which can optimise the interactions to the target protein, subsequently improving the 
binding affinity7. Furthermore, structural information for the target parasitic protein and 
comparisons to its homologous proteins can be exploited to design new compounds 
which are selective for their target. Structural information has underpinned many 
different anti-parasitic drug discovery projects, which have been reviewed 
elsewhere8,9. A recent example is the work by Philips et al. who targeted the 
Plasmodium falciparum dihydroorotate dehydrogenase (DHODH) enzyme. After a 
structure-based drug discovery programme the lead compound, DSM265, has 
reached phase II clinical trials emphasising the success of this approach10. However, 
there is a low percentage of structures deposited in the Protein Data Bank from 
parasitic organisms which can significantly hinder SBDD projects when homology 
models are not available. The challenges of obtaining parasitic structures are 
described below. 
 
2. Challenges Associated with Anti-Parasitic Structure Guided Drug Discovery 
 
Structure based inhibitor design is explicitly reliant upon structural information which 
has been typically  provided by X-ray crystallography and nuclear magnetic resonance 
(NMR)11. In the absence of a structure of the target protein, homology models can be 
generated which will approximate the target binding pocket. This is dependent on two 
things, the first is an accurate starting model on which to base the modelling and the 
second is sufficient sequence identity/similarity which provides confidence in the 
resulting model12. For parasitic targets this can provide a significant challenge in terms 
of pre-existing structures and sequence similarity with many targets being unique to 
the parasite family. Moreover, a common feature of many apicomplexan parasites is 
the presence of low complexity inserts which can vary significantly in length13. For 
example, enoyl reductase is the target of potent inhibitors, such as triclosan14. Within 
the apicomplexan family there is a low complexity insert situated around the inhibitor 
binding site15. A similar insert is seen with the M. tuberculosis family, which results in 
a significant enlargement of the inhibitor binding pocket16. For the apicomplexan 
family, crystallographic studies have shown that this insert does not alter the inhibitor 
binding pocket, as seen within the M. tuberculosis family, with the apicomplexan 
binding pocket adopting a very similar architecture to homologues without the insert 
(Figure 1)15. The role for the low complexity insert is currently unknown but could 
facilitate protein complex formation.  
 
In comparison, Birkholtz et al17 have shown that parasite-specific inserts in the P. 
falciparum S-adenosylmethionine decarboxylase/orinithine decarboxylase 
(PfAdoMetDC/ODC) are important for enzyme activity. These decarboxylase enzymes 
are critical in the synthesis of polyamines. There are four inserts in total which have 
effectively doubled the size of the AdoMetDC/ODC complex in comparison to its 
mammalian homologues. Each of the individual inserts were deleted and the activity 
of both decarboxylase enzymes was reduced. Thereby suggesting the insertions are 
important in mediating how the two enzymes interact and carry out their catalytic 
function. Another example of low complexity parasitic inserts being important to the 
function of the enzyme is shown by Yuvaniyama et al18. P. falciparum dihydrofolate 
reductase-thymidylate synthase (PfDHFR-TS) is an important therapeutic target for 
anti-malarial drugs and crystal structures have revealed three additional helical inserts 
in the enzyme. The function of two of these inserts has been determined from 
structural studies. One insert is composed of ten amino acids and could represent a 
recognition site for additional interactions which is important to the function of the 
enzyme. The other insert (containing four amino acids) is thought to be involved in 
both dimerization and domain organisation of the two different domains, DHFR and 
TS. As this sequence is unique to the parasitic enzyme it represents an exciting 
therapeutic target as small molecule inhibitors could be developed to disrupt this 
interaction.  
 
In other instances, there are significant differences between homologues from 
different species both at the sequence and structural level. For example, the F-
ATPases are large rotary machines which produce ATP in the final step of the 
mitochondrial electron transport chain19. There are many crystal and EM derived 
structures from mammalian and bacterial systems which show that the catalytic 
20±22
. 
Within Trypanosoma brucei (T. brucei) it has been shown that the complex contains 
22 subunits, of which 14 are unique to the parasite organism, as they have no 
recognizable eukaryotic homologues. Through electron tomography the structure of 
the T. brucei F-ATPase was determined at ~30 Å resolution revealing that the parasitic 
3 subunit exists in a pyramidal shape which is significantly different to its bovine 
homologue23. This suggests that the mechanism of ATP synthesis is not as highly 
conserved as previously thought and may occur by a different mechanism in parasitic 
protozoa. It also highlights how despite the strong architectural conservation of this 
fundamental protein complex within bacteria, plants and mammals, there are 
significant differences in the parasitic homologues, which are not easily predicted 
through computational modelling. Furthermore, the structure of the ATP synthase 
revealed that a key subunit invol
two unique fragments23. Despite being cleaved the complex is still able to synthesize 
ATP and it is not known how this affects the mechanism of ATP synthesis in parasitic 
organisms. Moreover, in P. falciparum the ATP synthase does not have homologues 
for key subunits such as the membrane bound subunit a, which is critical for proton 
translocation across the membrane, and the peripheral stalk subunits b and d24. Due 
to the apparent absence of these subunits, it is difficult to accurately model the 
structure of the complex as it is unknown how the subunits interact with one another 
within the complex based on our current structural understanding. Therefore, gaining 
high resolution structural information about the parasitic complex via EM would allow 
the mechanism of action to be established.  
 
Many therapeutic targets, for both mammalian and parasitic systems, are 
membrane proteins (eg GPCRs and ion channels) which are notoriously difficult to 
study25 . This has resulted in a lack of structural information for many classes of 
membrane proteins, not just in parasites but all species. Recent developments in EM 
(discussed below), improved crystallisation methods such as LCP (lipid cubic phase)26 
and improved membrane protein screens have started to address this problem but a 
scarcity of information remains27. This results in difficulties when generating reliable 
homology models which can be validated through biochemical means, for example 
mutational analysis or crosslinking.  An improvement in our basic structural 
understanding of parasitic membrane proteins is essential if we are to begin to develop 
new therapeutics against this important clade.  
    If there is no structural information, including a reliable model, for the target protein 
available experimental methods such as X-ray crystallography, NMR or EM are 
conducted to probe the inhibitor binding site. A pre-requisite for structure 
determination is the ability to obtain sufficient quantities of pure protein. For 
crystallography, milligrams of very high purity sample are typically needed to produce 
crystals that diffract to high resolution. A significant reduction in protein quantity is 
seen for EM which typically uses microgram quantities, but even this can be a 
challenge for many systems. Sufficient protein quantities can be achieved in two ways, 
the first is through cloning the target protein(s) and overexpressing in a suitable host, 
for example E. coli. The second route is where the protein is extracted, direct from the 
native source.  Traditionally structural biology has been underpinned by the ability to 
overexpress proteins in more amenable hosts, such as bacteria or yeast which can be 
easily cultured into high volumes28. There are significant hurdles for the 
overexpression of many parasitic proteins, especially those for Plasmodium where the 
AT composition of the genome is unusually high (~80%) making it difficult to express 
the genes in the traditional hosts29. Moreover, the composition of the genome also 
UHVXOWVLQDFKDQJHLQWKHFRGRQXVDJHZKLFKUHVXOWVLQDOLPLWDWLRQRQFHUWDLQW51$¶V
in more traditional expression hosts.  This can be overcome by using the RIG plasmid 
expression system which allows codons commonly used by Plasmodium to be over 
expressed thereby fixing the codon bias30. This involves expressing the raUHW51$¶V
such as Arg, Ile and Gly, which are rarely used in E. coli, in parallel to your gene of 
choice, resulting in high yields of Plasmodium proteins30. A significant limitation of this 
route is in the study of larger protein complexes which can be a significant hurdle due 
to the requirement of specific chaperones and complex formation pathways which 
cannot always be compensated for in other host organisms. 
 
     For some systems, the preferred route is often native source as this can mitigate 
any concerns with post translational modifications or the need for chaperones which 
might not be replicated in the expression host. This is exemplified by the vacuolar 
ATPase (V-ATPase) where in some species such as S. cerevisiae, the RAVE complex 
is involved in the assembly of the complex after it has dissociated in response to being 
deprived of glucose31. It has been shown that in the absence of RAVE, the V-ATPase 
complex shows both functional and structural defects, highlighting the importance of 
the chaperone in the assembly of the complex31. Obtaining protein from the native 
source is a viable option for some systems. For example, the ability to obtain 
significant quantities of bovine heart muscle has allowed sufficient quantities of the 
proteins involved in the mitochondrial electron transport chain to be extracted from the 
mitochondria. This is shown in the crystal structures of bovine complex I32, cytochrome 
bc1 (complex III)33 and the F-ATPase (complex V)34 where the proteins were extracted 
from the heart muscle. Furthermore, the structure of the porcine respiratory 
supercomplex (I1III2IV1), was determined using cryo-EM providing us with a unique 
insight into how the individual components of the electron transport chain interact with 
one another in the native tissue35. This approach is reliant on a natural abundance of 
the protein and an appropriate method of purification that does not rely on engineered 
tags, such as His or FLAG tags.  For parasitic organisms obtaining sufficient quantities 
of protein is challenging as the parasites are relatively small and are difficult to culture. 
Therefore, obtaining large (litres) volumes of culture becomes unfeasible or too costly 
for most projects.  
 
    For a number of parasitic small protein targets, X-ray crystallography and to a lesser 
extent NMR has been a powerful approach in structure determination. In total, there 
DUHVWUXFWXUHVIRUµP. falciparum only¶ in the PDB (as of June 2017) which can be 
broken down into 480 structures solved using X-ray crystallography, 19 using NMR 
and just 5 using EM (Figure 2a). Three of the most common entries are for triose-
phosphate isomerase (29), M1 family aminopeptidase (20) and L-lactate 
dehydrogenase (16), which have a variety of different ligands bound. Interestingly, of 
the 480 X-ray deposited structures, ~95% of these have a molecular weight lower than 
250 kDa (Figure 2b). Therefore, for larger protein complexes and membrane proteins 
which are typically difficult to express in high abundance, alternative approaches are 
needed. This review describes how recent advances in the EM field can address many 
of these challenges and provide a new alternative to structure determination to drive 
SBDD programs against parasitic targets.  
 
 
 
3. Resurgence in Electron Microscopy  
    (OHFWURQPLFURVFRS\KDVUHFHQWO\XQGHUJRQHDµUHVROXWLRQUHYROXWLRQ¶UHVXOWLQJLQDQ
increase in the number of high resolution protein structures being determined (Figure 
3)36. Recently its impact has been recognised through the award of the Nobel Prize in 
chemistry (2017) to Jacques Dubochet, Joachim Frank and Richard Henderson for 
³developing cryo-electron microscopy for the high-resolution structure determination 
RIELRPROHFXOHVLQVROXWLRQ´. The developments in the field have not just improved the 
resulting resolution but it can now study much smaller systems (~100kDa) than would 
have typically been studied previously. This is highlighted by the large increase in the 
total number of structures from EM being deposited into the protein data bank each 
year; 65 in 2012 compared to 408 deposited in 2016 alone. The reasons behind this 
increase is developments made to microscope stability, the detector technology and 
image processing algorithms37. 
 
    EM is no longer considered as a technique which can only be used for large 
symmetrical systems or large protein complexes such as viruses or ribosomes, 
respectively. A significant increase in the number of structures has been in the 
membrane protein field, which has traditionally proven to be highly challenging for 
crystallographic techniques38. For instance, high resolution structures of the 
membrane proteins TRPV139, Slo2.240, Cav1.141 and gamma secretase42 have been 
determined using EM approaches, with these targets previously evading 
crystallographic studies. By negating the need for highly ordered protein crystals which 
is often hindered by a lack of crystal contacts within detergent enclosed membrane 
proteins, EM is a powerful alternative for structure determination43. Given the number 
of parasitic membrane protein targets this is an exciting opportunity to open up new 
avenues in SBDD against previously intractable systems. Furthermore, EM is a 
powerful technique for determining the structure of large protein complexes which can 
enable individual proteins to be studied in a more native environment than their 
isolated individual structures. One such example is the respiratory supercomplex 
which has been determined at ~7 Å35 and more recently 4.0 Å44 by EM. The cryo-EM 
structures have enabled the overall architecture of the supercomplex to be understood 
despite there already being crystal structures of the individual components highlighting 
the complementary nature of the two techniques. 
 
    Over the past 5 years there has been an increasing number of smaller proteins 
(<250 kDa), studied using EM which is shown by there being ~29 unique, sub nm 
resolution maps deposited in the EMDB. Smaller systems can now be studied with the 
use of phase plates which increases the signal to noise ratio in the images, 
subsequently boosting the contrast which is needed to see the protein45,46. For 
instance, the smallest structure determined by cryo-EM is the structure of 
haemoglobin (~60 kDa) which was determined using the Volta phase plate at 3.2 Å 
resolution47. Previously the smallest protein determined was isocitrate dehydrogenase 
(93 kDa) which achieved a resolution of 3.8 Å48. This highlights the step-change EM 
has undergone in recent years as targets which were previously thought to be too 
small for EM are now being determined at high resolution.  
 
    'HVSLWHWKH³UHVROXWLRQUHYROXWLRQ´LQ(0WKHH[SHFWHGUHVROXWLRQLVVWLOOW\SLFDOO\a-
4 Å. Although not all side chains can be unambiguously assigned at this resolution, it 
has proven to be sufficient to characterise the inhibitor biding site in TRPV1 (2.9 Å)39 
and the proteasome (3.6 Å)49. Higher resolution has been achieved in the case of E-
galactosidase (2.2 Å)50 which reportedly resolved not only the bound inhibitor but also 
co-ordinating waters.  The ability to resolve inhibitor density and see how compounds 
interact with their target protein, means that EM has the potential to be used as a tool 
in SBDD48,51. Because of this improvement in resolution, it is now feasible that EM can 
play a role in elucidating structural information for parasitic proteins which have so far 
evaded structural characterisation. 
 
    One signifLFDQW OLPLWDWLRQ ZLWK FXUUHQW 6%'' DSSURDFKHV LV WKH XVH RI ³VWDWLF´
structures, whereby the target protein is determined in only one or a handful of 
conformational states. However, EM has become a powerful technique to study 
different conformational states and the dynamic nature of large protein complexes, 
with EM accounting for the flexibility of different systems in the data processing steps. 
For instance, the 3.4 Å structure of the human J-secretase identified a flexible active 
site which could change conformation upon substrate binding42. Additionally, the 
vacuolar ATPase has been shown to have inherent flexibility with the soluble, catalytic 
V1 domain moving in relation to the membrane bound V0 domain52. Moreover, the 
structure of the full Manduca V-ATPase was originally determined at 9.2 Å but using 
the same data set, masking of the individual V1 domain improved the resolution to 8.2 
Å with the local resolution showing further improvements to ~6 Å53. By accounting for 
the flexibility of the system, the resolution was substantially improved which could 
reveal new insights into the structure of dynamic systems. This can be advantageous 
over X-ray crystallography because upon formation of the crystal lattice, the protein 
can become trapped into one particular conformation. Comparing the different 
conformational states, which can be identified and separated using EM, will allow new 
inhibitors to be designed against the most populated, and potentially the most 
physiologically relevant state. For instance, obtaining structures of the F-ATPase via 
cryo-EM revealed the complex existed in three distinct conformations which could be 
sub-divided into seven different sub-states22. Furthermore, Hite et al have determined 
the structure of the Slo2.2 potassium channel in both an open and closed state via 
cryo-(0WKXVUHYHDOLQJWKHFKDQQHO¶VPHFKDQLVPRIDFWLRQVZLWFKLQJEHWZHHQWKHWZR
states, which is vital information when targeting particular states which predominate 
in the native environment54.  
 
    The recent resurgence in EM has been primarily underpinned by the introduction of 
direct electron detectors which has enabled the signal to noise ratio of the data to be 
improved resulting in higher contrast in the images55,56. Moreover, instead of taking 
single images, the detectors record movies containing a number of individual frames 
which have only been exposed to a small proportion of the total dose in a single 
exposure. This is advantageous because during a typical two second exposure, 
radiation damage to the sample and/or mechanical drift in the microscope can cause 
blurring of the image. Computational programmes can subsequently correct for this 
movement to further enhance the signal and quality of the images thus allowing the 
high-resolution information to be retained. Before the introduction of these detectors 
images were recorded on film or CCD cameras which do not record movies but instead 
take an average image of the movement during an exposure57. This resulted in the 
loss of the higher resolution information as the particle would appear to be blurred, 
significantly hindering the structural determination of the sample. Recording the 
exposures as movies instead of single images also allows one of the main limitations 
of EM to be mitigated; radiation damage58,59. As the sample is irradiated by the 
electron beam it undergoes significant amounts of radiation damage which can affect 
side chains by differing amounts. For instance, whilst taking a single micrograph, the 
sample is typically exposed to between 20-100 e-/Å2. However, it has been shown that 
doses as low as ~3e-/ Å2 can have a serious negative impact on some charged amino 
acids resulting in some high resolution information to be lost60. By removing the later 
frames, where the sample has been exposed to the highest amount of electrons, or 
by weighting the frames by the dose they have received, the radiation damage to some 
extent can be accounted for60.  
 
    Cryo-electron tomography is another technique which could be exploited to identify 
new parasitic drug targets within cells as individual cells can now be plunge-frozen 
and imaged61. This is particularly advantageous when the target protein cannot be 
extracted from its environment therefore traditional single particle analysis cannot be 
performed. In tomography, images are generally obtained as tilt-series which results 
from the specimen being imaged at a series of different angles in the microscope 
(typically between ± 65° with an image being taken at 2° increments). Comp utationally 
these images can then be recombined using subtomogram averaging methods, to 
generate a 3D model of the target macromolecular complex in situ62. The resolution 
achieved and the thickness of the sample being imaged are the main limitations of this 
technique. As multiple images are taken at the same position, low electron doses are 
used to prevent losing all of the biological information to radiation damage. Therefore, 
in order for the electrons to be detected the sample needs to be less than ~500 nm in 
thickness otherwise there would be no signal in the images63. Traditionally, resolutions 
obtained from cryo-tomography have been ~1-2 nm allowing for the organisation and 
globular shape of the protein to be understood. However, more recently the resolution 
of tomographic reconstructions has significantly improved as exemplified by the 
structure of the HIV-capsid-SP1 at 3.9 Å64. This suggests that in the future, high 
resolution structures derived from tomography could play an important role in 
elucidating how drugs can bind to their target protein in situ.  
 
4. Examples of Parasitic Structures determined using EM 
    Currently the EMDB contains many high-resolution EM structures of parasitic 
proteins including a number of ribosomal subunits from different parasitic species such 
as Trypanosoma brucei (5.6 Å)65, Trypanosoma cruzi (2.5 Å) (Figure 4A)66 and two 
from Leishmania donovani (2.8 Å and 2.9 Å)67,68. The most commonly studied parasitic 
protein in the EMDB is the P. falciparum 80S ribosome, with three different structures. 
One of which has revealed the dynamic features of the ribosome during translation, 
identified through 3D classification of the data69. This involves sorting the particles into 
classes based upon their different 3D structures. Therefore, if the protein exists in two 
distinct conformational states the particles which make up these states will be 
separated into two different classes thereby producing two 3D models. The other two 
structures are of the ribosome with two different anti-malarial drugs bound, Emetine70 
and Mefloquine71, highlighting the power of EM as a tool for visualising how ligands 
are bound to their target protein in anti-parasitic drug discovery. 
 
    Recently Wong et al have provided one of the first examples of a parasitic EM 
structure being used to drive anti-malarial inhibitor design71. By determining the 
structure of the P. falciparum 80S ribosome in the presence of Mefloquine, the study 
not only identified the mechanism of action of the compound, they also de novo 
designed a series of Mefloquine analogues which had improved anti-malarial activity 
based on the EM derived structure. The structure of the 80S ribosome was determined 
at 3.2 Å and clearly showed density for one enantiomer of the compound at the 
GTPase-associated centre of the large ribosomal subunit a. The binding site for the 
compound was probed to reveal the amino acid residues involved in binding to the 
compound which was used to design a series of derivatives which showed improved 
activity.  
 
    EM can play an important role in designing selective anti-parasitic inhibitors. This is 
highlighted by Li et al who determined the structure of the P. falciparum proteasome 
at 3.6 Å in the presence of an inhibitor (Figure 4B)72. The structure showed clear 
density for the peptide inhibitor which was covalently linked to the protein. 
Furthermore, the structures of Plasmodium and human proteasomes were compared 
to reveal the parasitic inhibitor binding site was more open than the human orthologue, 
which demonstrates how modelling alone based on sequence similarity cannot always 
account for the more subtle structural differences. This information can subsequently 
be utilised in the design of new compounds which are highly selective for the parasite 
protein thus enhancing the chances of creating new therapeutic drugs. 
 
Lower resolution structures obtained by electron cryo-tomography have also 
provided unique insights into the structure of parasitic proteins and how they interact 
with their host. One such example is by Akhouri et al. who have used tomography to 
identify how the P. falciparum Erythrocyte membrane protein 1 (PfEMP1) interacts 
with human IgM in parasitized red blood cells (pRBC)73. They found that PfEMP1 
clusters the human IgM on the pRBC surface which enables them to interact with 
uninfected red blood cells. In doing so, the parasites are able to avoid IgM mediated 
cell lysis. Another example by Lemgruber et al used cryo-electron tomography to study 
Plasmodium apicoplasts74. Previous to their work, it was unknown whether the 
Plasmodium apicoplast had three of four membranes. A tilt-series of images were 
taken and a 3D reconstruction showed that there were clearly four membranes in the 
apicoplast which was consistent with a number of different apicomplexan parasites. 
This highlights the importance of the technique in providing key information about an 
important organelle within a parasitic organism. 
 
5. Challenges for Electron Microscopy to Overcome 
    Despite the vast improvements in EM over the past five years, X-ray crystallography 
still remains the gold standard technique for structure based drug design75. The main 
advantage for X-ray crystallography over EM is the resolution of the structures 
obtained. For instance, high resolution structures of ~1-2 Å are routinely solved by 
crystallography. At this resolution, the position of water molecules and coordinating 
metal ions can be established which provides atomic level detail which is rarely seen 
in EM. This is further utilised when analysing modes of inhibitor binding as high 
resolution crystal structures can highlight the non-covalent interactions made to the 
protein. Whilst the number of high resolution structures being produced by EM is 
increasing, there are still numerous hurdles, such as resolution, for EM to overcome 
in the future. 
 
    Where protein is readily available, stable and homogeneous then X-ray 
crystallography is often the primary route for structural determination. An advantage 
of X-ray crystallography over EM is the speed of data collection as many different 
crystals, which could be complexed with a variety of different inhibitors, can be 
screened and processed within a day. For EM, the number of particles which are 
needed to obtain high resolution structural information can vary between ~50,000 to 
1,000,000 particles depending on the protein sample56. This requires thousands of 
individual images to be collected over several days before data processing can begin. 
Large data sets can be generated using software which allows for automated data 
acquisition. The current speed of the detectors can vary between 50-150 images per 
hour depending on the camera which is used and the mode of data collection. For 
instance, integrated mode on the Falcon III can take up to ~150 images per hour but 
when it is on the more sensitive counting mode the number of exposures per hour is 
reduced to ~40. 
 
    Once all of the data has been collected the time taken to go from raw micrograph 
to 3D model can be between ~1-4 weeks depending on the amount of data which has 
been collected. The speed of data processing is improving and has been significantly 
enhanced via graphical processing unit (GPU) cards76. This has greatly increased the 
speed of the initial processing steps such as motion correction, CTF correction and 
auto-picking whilst also improving the speeds of the classification and refinement 
steps of the processing77. Furthermore, there will be more emphasis on the initial on-
the-fly processing which will increase the speed of the image processing as the 
individual movies will be motion-corrected and CTF corrected as they are being taken. 
Another hurdle for EM to overcome is the amount of data generated per data 
collection. For instance, if each individual movie file is ~1.5 GB in size, a data collection 
of ~3,000 micrographs will result in ~4.5 TB of raw data being produced. Processing 
the data will further increase the amount of data generated therefore the computational 
power and subsequent storage of the data represents a huge challenge in the EM 
community as the appropriate computational infrastructure needs to be in place. Most 
funding bodies in the UK also require data to be stored for at least ten years which 
means that both short and long term storage plans need to be executed. 
 
    One of the biggest challenges in the EM field is radiation damage which occurs 
when the specimen is exposed to the electron beam. It has been described that 
sufficient exposure to the electron beam in order to obtain an image has the same 
effect on the specimen as standing next to a nuclear detonation, therefore the level of 
sample irradiation needs to be kept to a minimum in order to minimise the loss of high 
resolution structural information78,79. When the beam of electrons first hits the 
specimen, it causes the biggest movement of the particles in the ice, which is thought 
to be caused by charging or contraction between the carbon support and the metal 
grid bars on the grid80. This beam-induced movement of the particles causes some of 
the highest resolution information to be lost as the particles have not yet suffered from 
radiation damage. If this information can be restored then the resolution which EM 
could achieve will be further increased. However, fully understanding and limiting the 
factors that cause the initial movement of the specimen during initial beam exposure 
will be a significant challenge. 
 
    Another limitation which currently hinders EM is the amount of contrast in the 
individual micrographs. This means that small samples, such as ~100 kDa proteins, 
are difficult to see without using high levels of defocus which subsequently limits the 
high-resolution information in the image81. This reduction in signal to noise for smaller 
samples is problematic for downstream processing of the data for example when 
picking particles and/or aligning and classifying the data. In order to improve the 
contrast in the images, without applying the high levels of defocus, phase plates can 
be used. For instance the structure of haemoglobin and Prx3 which were  determined 
at 3.2 Å and 4.4 Å, respectively, using the phase plate which significantly improved 
the contrast in the raw micrographs45,82. This technology is still in its infancy and further 
work needs to be carried out before it becomes routinely used. 
 
6. Future prospects 
    Despite using less protein than X-ray crystallography, EM still requires ~3-5 µL of 
pure sample per grid (typically at ~1mg/ml) which can be challenging to obtain from 
parasitic organisms. Currently EM grids are prepared by applying ~3 µL of sample 
onto the grid, blotting the majority of this away using filter paper and then plunge-
freezing this into liquid ethane leaving the sample suspended in a thin layer of vitreous 
ice. The disadvantages of this approach are that it can be unreliable, inconsistent and 
as most of the sample is blotted away it can waste precious material. Therefore, more 
efficient ways of grid preparation are being developed which involve spraying pico-
litres of sample directly onto the grid83. Using this method, it would also be possible to 
have numerous protein samples applied onto different areas of the same grid which 
would enable more efficient ways to screen numerous samples, ie protein with 
different ligands bound.  
 
    Moreover, on-grid purification techniques are currently being developed which 
would also significantly reduce the amount of purified protein needed for grid 
preparation. Two different approaches have been developed for this. The first involves 
creating a Nickel monolayer on the surface of the grid thus extracting any His-tagged 
proteins directly onto the grid84. The second approach involves using immobilised 
antibodies onto the surface of the grid so the target protein becomes attached to the 
surface85. This is particularly useful for proteins where obtaining high quantities from 
traditional purification columns can be challenging. By purifying directly onto the grid, 
less protein is needed, therefore this could prove a vital tool in determining parasitic-
derived structures.  
 
    As already discussed, EM is a useful tool for studying dynamic systems which are 
not constrained by the crystal lattice. These conformational changes, which occur on 
a 10-1000 ms timescale, can be monitored using EM via flash freezing the sample at 
different time-points in a biological reaction86. This could be useful in monitoring any 
conformational changes which occur upon formation of a large macromolecular 
complex or upon binding of a ligand. So far, time-resolved EM has provided useful 
insights into the catalytic cycle of the ribosome87. Currently developments are being 
made to the rapid mixing/spraying of the sample onto the grid before it is plunge-
frozen88. By being able to trap biological systems at different time points, key insights 
into the mechanism of action of many complexes and the flexibility of inhibitor binding 
sites can be gained which will enhance future drug discovery projects. 
 
7. Concluding Comments 
    The rapid advances in EM has given rise to a huge increase in the number of 
structures routinely being determined to high resolution. Due to the improved 
resolution of the structures being determined, EM can now be considered as a tool in 
structure based drug design. By moving away from the static snapshots provided by 
X-ray crystallography, EM can be used to study dynamic and flexible systems. This 
will aid SBDD programmes as the dynamic nature of inhibitor binding sites can be 
probed thus allowing inhibitors to be designed against the most physiologically 
relevant states. Despite the large improvements in EM, the technique is still in its 
infancy and future developments within the field are inevitable. In addition to 
established techniques such as X-ray crystallography and NMR, EM can now be used 
to elucidate the structural information of parasitic protein targets thereby enabling a 
new generation of inhibitors to be designed.  
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Figures 
 
 Figure 1: Low complexity insert in T. gondii enoyl reductase (ENR). The parasitic 
insert can vary between ~5-40 amino acid residues. In T. gondii the parasitic insert, 
consisting of 5 amino acid residues, is shown in red and is in close proximity to the 
inhibitor (cyan) binding site (pdb 2o2s)15. 
 
 
 
 
 
 
Figure 2: The number of P. falciparum structures deposited in the protein data bank 
(pdb). A) A pie chart highlighting the percentage of structures deposited into the pdb 
according to the technique used. B) The proteins deposited into the pdb according to 
technique used and molecular weight. This shows that EM is an important tool for proteins 
with a molecular weight greater than 250 kDa as there are fewer X-ray crystal structures 
solved for higher molecular weights. The numbers were accurate as of June 2017.  
 
  
 
Figure 3: The trend showing the highest resolution EM map each year. The 
highest resolution map deposited in the EMDB each year between 2002-2017.  
 
 
 
 
 
 
 Figure 4: Examples of parasitic structures determined by EM. A) The highest 
resolution structure determined from a parasitic organism of the T. cruzi ribosome at 
2.5 Å (EMDB 8361, pdb 5t5h)66 with example density of DNA (right). B) The 3.6 Å 
structure of the P. falciparum proteasome (EMDB3231, pdb 5fmg)72 with density for 
the covalently bound peptide inhibitor (right). 
 
 
 
 
 
 
